RPAM
CMPX icon

Rhenman & Partners Asset Management’s Compass Therapeutics CMPX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-115,113
Closed -$609K – 102
2026
Q1 		$609K Buy
+115,113
New +$664K 0.08% 86

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rhenman & Partners Asset Management's CMPX Position: Q2 2026 in Review

Rhenman & Partners Asset Management sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 115,113 shares — an estimated $609K sold.

Rhenman & Partners Asset Management first reported a position in CMPX in Q1 2026 and held it in 1 quarter. The position peaked at $609K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Rhenman & Partners Asset Management reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 115,113 Compass Therapeutics shares in Q2 2026, an estimated $609K.
  • Rhenman & Partners Asset Management first reported a position in Compass Therapeutics in Q1 2026 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Compass Therapeutics position peaked at $609K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.